Mutant p53: “gain of function” through perturbation of nuclear structure and function?
✍ Scribed by Wolfgang Deppert; Thomas Göhler; Hisashi Koga; Ella Kim
- Publisher
- John Wiley and Sons
- Year
- 2000
- Tongue
- English
- Weight
- 148 KB
- Volume
- 79
- Category
- Article
- ISSN
- 0730-2312
No coin nor oath required. For personal study only.
📜 SIMILAR VOLUMES
## Background: Neuroblastomas often acquire sustained drug resistance during therapy. sensitivities to carboplatin, etoposide, or melphalan were determined for 18 neuroblastoma cell lines; eight were sensitive and ten were resistant. as p53 mutations are rare in neuroblastomas studied at diagnosis,
Loss of wild-type p53, either through deletion or mutation, has been demonstrated in most squamous cell carcinomas of the head and neck (HNSCC). Whether these mutant molecules contribute to tumor progression purely through loss of wild-type functions or by growth-promoting mechanisms, however, remai
We previously reported clonal expansion of p53 mutations in malignant astrocytic tumors detected with a yeast p53 functional assay that measures mutant p53 alleles quantitatively and loss of p53 transcriptional competence qualitatively (Tada et al., Int J Cancer 67:447-450, 1996). This method select